Hepatic Hilar Nerve Block for Adjunctive Analgesia in Thermal Ablation of Liver Tumors: A Prospective Randomized Controlled Trial

To determine whether performing a temporary hepatic hilar nerve block in patients undergoing microwave or radiofrequency ablation of primary or secondary hepatic malignancies reduces the requirement for intravenous conscious procedural sedation and analgesia.Fifty patients undergoing percutaneous image-guided liver thermal ablation were included in this single-center prospective randomized controlled trial. The experimental arm received a hepatic hilar nerve block in addition to intravenous medication directly before thermal ablation, whereas the control group underwent thermal ablation solely under intravenous medication, with the possibility of crossover. Student's t-test and analysis of covariance were performed to determine the block's efficacy regarding the intraoperative medication requirement.50 patients (22 females, 28 males) were randomly allocated to two groups without significant differences between the cohorts' baseline patient, clinical, and tumor characteristics. Three control group patients underwent crossover. Initial analysis using Student's t-test revealed no significant intravenous medication reduction in the control group vs. the test group (190 µg vs. 189 µg fentanyl, P = 0.96 and 1.34 mg vs. 1.60 mg Midazolam, P = 0.19). Thus, ANCOVA was performed to accommodate for heterogeneous ablation conditions (ablation time, total energy applied, affected liver capsule area). The adjusted mean fentanyl dosage was 206 µg vs. 184 µg (control group vs. test group), yielding a significant reduction after block (P = 0.020). None of the patients who received a hepatic hilar nerve block experienced any adverse events during a mean follow-up of nearly six months (range: 0-17 months).This prospective randomized trial confirms that a hepatic hilar nerve block can be safely performed before liver tumor thermal ablation as an adjunct to intravenous medication to reduce opioid consumption and manage pain. · First randomized study evaluating hepatic hilar nerve block (HHNB) for liver tumor ablation.. · HHNB significantly reduced opioid use after adjusting for heterogeneous ablation conditions.. · The effect is less pronounced than in retrospective studies. Larger trials are needed.. · Georgiades M, March C, Barajas Ordonez F et al. Hepatic Hilar Nerve Block for Adjunctive Analgesia in Thermal Ablation of Liver Tumors: A Prospective Randomized Controlled Trial. Rofo 2025; 197: 1426-1432.

Authors

Institutions

Publication Details

Journal
RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
Published
2025-02-20
DOI
https://doi.org/10.1055/a-2528-7037
Citations
1
Primary Topic
Vagus Nerve Stimulation Research
Type
article
Field-Weighted Citation Impact
0.84
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Hepatic Hilar Nerve Block for Adjunctive Analgesia in Thermal Ablation of Liver Tumors: A Prospective Randomized Controlled Trial

Jazan Omari, Felix Barajas Ordonez, Oliver S. Großer, Maciej Powerski et al.
1 citations
RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
Vagus Nerve Stimulation Research
0.84
article

Hepatic Hilar Nerve Block for Adjunctive Analgesia in Thermal Ablation of Liver Tumors: A Prospective Randomized Controlled Trial

Jazan Omari, Felix Barajas Ordonez, Oliver S. Großer, Maciej Powerski, Christine March, Maciej Pech, Marilena Georgiades, Robert Damm
article en
1 citations

Abstract

To determine whether performing a temporary hepatic hilar nerve block in patients undergoing microwave or radiofrequency ablation of primary or secondary hepatic malignancies reduces the requirement for intravenous conscious procedural sedation and analgesia.Fifty patients undergoing percutaneous image-guided liver thermal ablation were included in this single-center prospective randomized controlled trial. The experimental arm received a hepatic hilar nerve block in addition to intravenous medication directly before thermal ablation, whereas the control group underwent thermal ablation solely under intravenous medication, with the possibility of crossover. Student's t-test and analysis of covariance were performed to determine the block's efficacy regarding the intraoperative medication requirement.50 patients (22 females, 28 males) were randomly allocated to two groups without significant differences between the cohorts' baseline patient, clinical, and tumor characteristics. Three control group patients underwent crossover. Initial analysis using Student's t-test revealed no significant intravenous medication reduction in the control group vs. the test group (190 µg vs. 189 µg fentanyl, P = 0.96 and 1.34 mg vs. 1.60 mg Midazolam, P = 0.19). Thus, ANCOVA was performed to accommodate for heterogeneous ablation conditions (ablation time, total energy applied, affected liver capsule area). The adjusted mean fentanyl dosage was 206 µg vs. 184 µg (control group vs. test group), yielding a significant reduction after block (P = 0.020). None of the patients who received a hepatic hilar nerve block experienced any adverse events during a mean follow-up of nearly six months (range: 0-17 months).This prospective randomized trial confirms that a hepatic hilar nerve block can be safely performed before liver tumor thermal ablation as an adjunct to intravenous medication to reduce opioid consumption and manage pain. · First randomized study evaluating hepatic hilar nerve block (HHNB) for liver tumor ablation.. · HHNB significantly reduced opioid use after adjusting for heterogeneous ablation conditions.. · The effect is less pronounced than in retrospective studies. Larger trials are needed.. · Georgiades M, March C, Barajas Ordonez F et al. Hepatic Hilar Nerve Block for Adjunctive Analgesia in Thermal Ablation of Liver Tumors: A Prospective Randomized Controlled Trial. Rofo 2025; 197: 1426-1432.

RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden VerfahrenVol. 197(12)
Städtisches Klinikum Dessau (DE), University Hospital Magdeburg (DE), Otto-von-Guericke-Universität Magdeburg (DE)
Openalex Percentile: Top 30%
Vagus Nerve Stimulation Research
0.84
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.